1046 related articles for article (PubMed ID: 18043443)
1. Intravenous palivizumab and ribavirin combination for respiratory syncytial virus disease in high-risk pediatric patients.
Chávez-Bueno S; Mejías A; Merryman RA; Ahmad N; Jafri HS; Ramilo O
Pediatr Infect Dis J; 2007 Dec; 26(12):1089-93. PubMed ID: 18043443
[TBL] [Abstract][Full Text] [Related]
2. A multi-drug regimen for respiratory syncytial virus and parainfluenza virus infections in adult lung and heart-lung transplant recipients.
Liu V; Dhillon GS; Weill D
Transpl Infect Dis; 2010 Feb; 12(1):38-44. PubMed ID: 19761558
[TBL] [Abstract][Full Text] [Related]
3. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.
Pediatrics; 1998 Sep; 102(3 Pt 1):531-7. PubMed ID: 9738173
[TBL] [Abstract][Full Text] [Related]
4. Prophylaxis in RSV infection (Palivizumab)--is it worthwhile?
Hashmi NA; Cosgrove JF; MacMahon P
Ir Med J; 2000 Dec; 93(9):284. PubMed ID: 11209917
[TBL] [Abstract][Full Text] [Related]
5. Respiratory syncytial virus infection in patients with hematological diseases: single-center study and review of the literature.
Khanna N; Widmer AF; Decker M; Steffen I; Halter J; Heim D; Weisser M; Gratwohl A; Fluckiger U; Hirsch HH
Clin Infect Dis; 2008 Feb; 46(3):402-12. PubMed ID: 18181739
[TBL] [Abstract][Full Text] [Related]
6. Respiratory syncytial virus infection in recipients of allogeneic stem-cell transplantation: a retrospective study of the incidence, clinical features, and outcome.
Avetisyan G; Mattsson J; Sparrelid E; Ljungman P
Transplantation; 2009 Nov; 88(10):1222-6. PubMed ID: 19935377
[TBL] [Abstract][Full Text] [Related]
7. Prophylaxis and treatment of respiratory syncytial virus in adult immunocompromised patients.
Hynicka LM; Ensor CR
Ann Pharmacother; 2012 Apr; 46(4):558-66. PubMed ID: 22395247
[TBL] [Abstract][Full Text] [Related]
8. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage.
Romero JR
Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S46-54. PubMed ID: 12671452
[TBL] [Abstract][Full Text] [Related]
9. Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants.
Pedraz C; Carbonell-Estrany X; Figueras-Aloy J; Quero J;
Pediatr Infect Dis J; 2003 Sep; 22(9):823-7. PubMed ID: 14506376
[TBL] [Abstract][Full Text] [Related]
10. Intravenous ribavirin is a safe and cost-effective treatment for respiratory syncytial virus infection after lung transplantation.
Glanville AR; Scott AI; Morton JM; Aboyoun CL; Plit ML; Carter IW; Malouf MA
J Heart Lung Transplant; 2005 Dec; 24(12):2114-9. PubMed ID: 16364859
[TBL] [Abstract][Full Text] [Related]
11. Palivizumab for respiratory syncytial virus prophylaxis.
Sandritter T
J Pediatr Health Care; 1999; 13(4):191-5; quiz 196-7. PubMed ID: 10690084
[TBL] [Abstract][Full Text] [Related]
12. Palivizumab prophylaxis and hospitalization for respiratory syncytial virus disease in the Stockholm infant population, 1999 through 2002.
Henckel E; Luthander J; Berggren E; Kapadia H; Naver L; Norman M; Bennet R; Eriksson M
Pediatr Infect Dis J; 2004 Jan; 23(1):27-31. PubMed ID: 14743042
[TBL] [Abstract][Full Text] [Related]
13. Physiologic risk factors for respiratory viral infections and immunoprophylaxis for respiratory syncytial virus in young children with congenital heart disease.
Cabalka AK
Pediatr Infect Dis J; 2004 Jan; 23(1 Suppl):S41-5. PubMed ID: 14730269
[TBL] [Abstract][Full Text] [Related]
14. Respiratory syncytial virus and parainfluenza virus infections in the immunocompromised host.
Wendt CH; Hertz MI
Semin Respir Infect; 1995 Dec; 10(4):224-31. PubMed ID: 8668850
[TBL] [Abstract][Full Text] [Related]
15. Combination therapy with aerosolized ribavirin and intravenous immunoglobulin for respiratory syncytial virus disease in adult bone marrow transplant recipients.
Whimbey E; Champlin RE; Englund JA; Mirza NQ; Piedra PA; Goodrich JM; Przepiorka D; Luna MA; Morice RC; Neumann JL
Bone Marrow Transplant; 1995 Sep; 16(3):393-9. PubMed ID: 8535312
[TBL] [Abstract][Full Text] [Related]
16. Improved outcomes with home-based administration of palivizumab: results from the 2000-2004 Palivizumab Outcomes Registry.
Frogel M; Nerwen C; Boron M; Cohen A; VanVeldhuisen P; Harrington M; Groothuis J;
Pediatr Infect Dis J; 2008 Oct; 27(10):870-3. PubMed ID: 18776822
[TBL] [Abstract][Full Text] [Related]
17. Incidence of respiratory syncytial virus-related hospitalizations in high-risk children: follow-up of a national cohort of infants treated with Palivizumab as RSV prophylaxis.
Lacaze-Masmonteil T; Rozé JC; Fauroux B;
Pediatr Pulmonol; 2002 Sep; 34(3):181-8. PubMed ID: 12203846
[TBL] [Abstract][Full Text] [Related]
18. Prophylaxis against respiratory syncytial virus in young children with cystic fibrosis.
Giebels K; Marcotte JE; Podoba J; Rousseau C; Denis MH; Fauvel V; Laberge S
Pediatr Pulmonol; 2008 Feb; 43(2):169-74. PubMed ID: 18085710
[TBL] [Abstract][Full Text] [Related]
19. Respiratory syncytial virus immune globulin treatment of lower respiratory tract infection in pediatric patients undergoing bone marrow transplantation - a compassionate use experience.
DeVincenzo JP; Hirsch RL; Fuentes RJ; Top FH
Bone Marrow Transplant; 2000 Jan; 25(2):161-5. PubMed ID: 10673674
[TBL] [Abstract][Full Text] [Related]
20. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections.
American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn
Pediatrics; 2003 Dec; 112(6 Pt 1):1442-6. PubMed ID: 14654627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
